ReviewEuropean journal of nuclear medicine and molecular imaging2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- The performance ofAsian journal of andrologyPooled it
- Trial
- Real-world Israeli single institution experience with PET-PSMA for staging of patients with clinically staged localized prostate carcinoma.Cancer reports (Hoboken, N.J.) · 2021Trial
- Trial
- Prospective Evaluation of PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targetedAnnals of nuclear medicine · 2019Trial
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.JAMA oncology · 2019Trial
- Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.European urology oncology · 2019Trial
- Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.European urology open science · 2026Article
- Evidence of anorectal involvement by prostate cancer on GA-68-PSMA-11 PET/CT portends inguinal nodal metastasis.Radiology case reports · 2026Article
- Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.Abdominal radiology (New York) · 2026Review
- Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- Diagnostic Accuracy of [Cancers · 2026Article
- Head-to-head comparison betweenJournal of translational medicine · 2026Article
- Superiority of long axial field-of-viewEuropean journal of nuclear medicine and molecular imaging · 2026Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care.
conclusionsAs PSMA-targeted PET is expected to be evaluated in larger prospective trials, the dissemination of potential diagnostic pitfalls and the biologic underpinning of those findings will be of increased importance.
Indexed as
Identifiers
28765998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.